On the stock market since 2013, it operates in the world of health and science. It has 1,624 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 43% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $781.9M a year; the problem isn’t sales — it’s costs running above that number.
There is $866.3M in the vault; even if every debt were paid off, $717.7M would remain.
A loss of $160.4M against $781.9M in annual sales.
The stock sits at $0.15. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, SPMXF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SPMXF has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.